News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
FDA
Sanofi-Aventis (France) Recalls 800000 H1N1 Vaccine Over Potency
December 15, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
BOSTON (MarketWatch) -- Sanofi-Aventis is recalling about 800,000 doses of its U.S.-distributed H1N1 vaccine for children after tests showed that certain batches had lost their potency over time, the Centers for Disease Control said Tuesday.
Twitter
LinkedIn
Facebook
Email
Print
FDA
Approvals
Europe
Sanofi
MORE ON THIS TOPIC
Approvals
Regeneron racks up another first as FDA greenlights generalized myasthenia gravis RNA drug
November 19, 2026
·
3 min read
·
Heather McKenzie
Approvals
Sanofi secures first FDA approval to treat neurological symptoms in rare metabolic disease
November 19, 2026
·
2 min read
·
Tristan Manalac
Insights
The untapped potential of drug repurposing
November 19, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Job Trends
Ramping up: 3 biotechs growing their workforce after series C raises
November 19, 2026
·
4 min read
·
Angela Gabriel